| A previously unrecognized mechanism for controlling the activity of YAP that is crucial for its oncogenic function mediated by mitotic dysregulation. | None |
| Studies indicate that yes-associated protein (YAP)-1 plays a dual role as oncogene and tumor suppressor gene in oncogenesis, depending on the specific tissue type involved. | None |
| Molecular evolution of the Yap/Yorkie proto-oncogene and elucidation of its core transcriptional program. | None |
| YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. | None |
| YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. | None |
| YAP1 takes over when oncogenic K-Ras slumbers. | None |
| results indicate a potential regulatory role of PTPN14 in the Hippo pathway and demonstrate another layer of regulation in the YAP oncogenic function | None |
| Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene. | None |
| the oncogenic activity of Ras(V12) depends on its ability to counteract Hippo pathway activity, creating a positive feedback loop, which depends on stabilization of YAP1. | None |
| The activation of the AXL/MAPK pathway was involved in the oncogenic functions of YAP1 in GBC. | None |
| Oncoprotein YAP regulates the spindle checkpoint activation in a mitotic phosphorylation-dependent manner through up-regulation of BubR1. | None |
| KIBRA functions co-operatively with the protein tyrosine phosphatase PTPN14 to trigger mechanotransduction-regulated signals that inhibit the nuclear localization of oncogenic transcriptional co-activators YAP/TAZ. Our results argue that the selective advantage produced by 5q loss involves reduced dosage of KIBRA, promoting oncogenic functioning of YAP/TAZ in TNBC. | None |
| miR-550a-3-5p acts as a tumor suppressor through the targeting of oncogenic YAP. | None |
| Because of divergent evolution of key interface residues, MST4 and MOB4 could disrupt assembly of the MST1-MOB1 complex through alternative pairing and thereby increased YAP activity. Collectively, these findings identify the MST4-MOB4 complex as a noncanonical regulator of the Hippo-YAP pathway with an oncogenic role in PC | None |
| ARID1A-containing SWI/SNF complex (ARID1A-SWI/SNF) operates as an inhibitor of the pro-oncogenic transcriptional coactivators YAP and TAZ | None |